Real-World Effectiveness of Ad26.COV2.S Adenoviral Vector Vaccine for COVID-19 – The Lancet   Commentary on Twitter One of the first studies to assess real-world effectiveness of the J&J 1-dose vaccine, matches Phase 3 clinical trial, at 77%https://t.co/3YgcML9YSh @MayoClinic @MayoClinicHS preprint pic.twitter.com/XOjQlUaHK2 — Eric Topol (@EricTopol) May 11, 2021  

The post [Preprint] Observational study finds single-dose Johnson & Johnson vaccine is 76.7% effective in preventing SARS-CoV-2 infection appeared first on Links Medicus.